对于已接受过放疗的患者采用125I间质内近距放疗治疗局部复发性腮腺癌的初步结果

Zhang, J.; Department of Oral and Maxillofacial Surgery, Peking University School, Hospital of Stomatology, Beijing, China

Background The purpose of this study was to analyze the treatment of recurrent parotid gland cancers with radioactive iodine ( 125I) seed implantation. Methods Fifteen patients with recurrent previously irradiated parotid gland cancers were treated with postoperative 125I seed implantation between April 2004 and June 2009. Local control, survival rates, and side effects were retrospectively reviewed. Results The 3-year and 5-year local control rates were 67% and 53.6%, and the overall survival rates were 76.2% and 66.7%, respectively. Four patients with House-Brackman (H-B) grade IV cancer recovered to grade II during follow-up. Four patients (26.7%) developed grade IV skin ulceration. Two patients (13.3%) developed moderate fibrosis of the subcutaneous tissues, and 2 patients (13.3%) had hearing loss for 1 year after brachytherapy. Conclusion This study showed excellent local control and a good survival rate in patients who received 125I brachytherapy. These findings should be interpreted cautiously due to the small number of patients and the relatively short follow-up. © 2012 Wiley Periodicals, Inc. Head Neck, 2012 Copyright © 2012 Wiley Periodicals, Inc.

Department of Oral and Maxillofacial Surgery, Peking University School, Hospital of Stomatology, Beijing, China